Repros Therapeutics Inc. (RPRX) Stock Price Down 1.4%
Repros Therapeutics Inc. (NASDAQ:RPRX) dropped 1.4% during trading on Wednesday . The stock traded as low as $2.03 and last traded at $2.08, with a volume of 93,398 shares trading hands. The stock had previously closed at $2.11.
Separately, Zacks Investment Research raised Repros Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Repros Therapeutics presently has an average rating of “Hold” and an average price target of $2.25.
The stock has a 50-day moving average of $1.94 and a 200-day moving average of $1.66. The company’s market cap is $48.76 million.
Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. Equities research analysts anticipate that Repros Therapeutics Inc. will post ($0.70) earnings per share for the current fiscal year.
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.